专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009115609A1 The calcium sensor STIM1 and the platelet SOC channel Orai1 (CRACM1) are essential for pathological thrombus formation 审中-公开
标题翻译：钙传感器STIM1和血小板SOC通道Orai1（CRACM1）对于病理性血栓形成至关重要
公开(公告)号：WO2009115609A1
公开(公告)日：2009-09-24
申请号：PCT/EP2009/053330
申请日：2009-03-20
申请人： CSL Behring GmbH , JULIUS-MAXIMILIANS UNIVERSITÄT WÜRZBURG , Braun, Attila , Kleinschnitz, Christoph , Nieswandt, Bernhard , Stoll, Guido , Varga-Szabó, Dávid
发明人： Braun, Attila , Kleinschnitz, Christoph , Nieswandt, Bernhard , Stoll, Guido , Varga-Szabó, Dávid
IPC分类号： A61K39/395 , A61P7/02
CPC分类号： C07K16/28 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0375 , A01K2267/0381 , C07K14/705 , C12N15/8509
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1 ) or an inhibitor of STIM1 - regulated plasma membrane calcium channel activity, in particular an inhibitor of Oraii (also designated as CRACM1 ), and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates to an inhibitor of stromal interaction molecule 1 (STIM1 ) or an inhibitor of ST I M1 -regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1 ), for treating and/or preventing a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及一种药物组合物，其包含基质相互作用分子1（STIM1）抑制剂或STIM1调节的质膜钙通道活性抑制剂，特别是Oraii抑制剂（也称为CRACM1）和任选的药物活性物质载体，赋形剂或稀释剂。本发明还涉及基质相互作用分子1（STIM1）抑制剂或ST I M1调节性质膜钙通道活性抑制剂，特别是Orai1抑制剂（也称为CRACM1），用于治疗和/或预防与静脉或动脉血栓形成有关的紊乱。

2. 发明公开

EP2262532A1 The calcium sensor STIM1 and the platelet SOC channel Orai1 (CRACM1) are essential for pathological thrombus formation 审中-公开
标题翻译：钙传感器STIM1和血小板SOC通道Orai1（CRACM1）作为用于病理性血栓形成要素
公开(公告)号：EP2262532A1
公开(公告)日：2010-12-22
申请号：EP09721489.4
申请日：2009-03-20
申请人： CSL Behring GmbH , Julius-Maximilians-Universität Würzburg
发明人： Braun, Attila , Kleinschnitz, Christoph , Nieswandt, Bernhard , Stoll, Guido , Varga-Szabó, Dávid
IPC分类号： A61K39/395 , A61P7/02
CPC分类号： C07K16/28 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0375 , A01K2267/0381 , C07K14/705 , C12N15/8509
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1 ) or an inhibitor of STIM1 - regulated plasma membrane calcium channel activity, in particular an inhibitor of Oraii (also designated as CRACM1 ), and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates to an inhibitor of stromal interaction molecule 1 (STIM1 ) or an inhibitor of ST I M1 -regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1 ), for treating and/or preventing a disorder related to venous or arterial thrombus formation.

3. 发明公开

EP2103311A1 The calcium sensor STIM1 is essential for pathological thrombus formation 审中-公开
标题翻译：电感传感器STIM1
公开(公告)号：EP2103311A1
公开(公告)日：2009-09-23
申请号：EP08005320.0
申请日：2008-03-20
申请人： CSL Behring GmbH , Julius-Maximilians-Universität Würzburg
发明人： Braun, Attila , Kleinschnitz, Christoph , Nieswandt, Bernhard , Stoll, Guido , Varga-Szabó, Dávid
IPC分类号： A61K39/395 , A61P7/02
CPC分类号： A61K39/395 , Y02A50/414
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of an activator of STIM1 and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates to an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of an activator of STIM1 for treating or preventing a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及一种药物组合物，其包含基质相互作用分子1（STIM1）的抑制剂或STIM1的活化剂的抑制剂和任选的药物活性载体，赋形剂或稀释剂。本发明还涉及基质相互作用分子1（STIM1）的抑制剂或STIM1的活化剂的抑制剂，用于治疗或预防与静脉或动脉血栓形成相关的病症。

4. 发明公开

EP2269597A1 CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis 审中-公开
标题翻译： CLEC-2蛋白酶抑制剂
公开(公告)号：EP2269597A1
公开(公告)日：2011-01-05
申请号：EP09008143.1
申请日：2009-06-22
申请人： CSL Behring GmbH , Julius-Maximilians-Universität Würzburg
发明人： Nieswandt, Bernhard , May, Frauke
IPC分类号： A61K31/00 , A61K39/395 , C07K16/28 , G01N33/53
CPC分类号： G01N33/5044 , A61K39/39541 , A61K39/3955 , A61K2039/505 , C07K16/2803 , C07K2317/55 , C07K2319/30 , G01N2333/4724 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2 and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2 for use in treating or preventing a disorder related to venous or arterial thrombus formation or as a lead compound for developing a drug for treating or preventing a disorder related to venous or arterial thrombus formation. The present invention also relates to a method of treating and/or preventing a disorder related to venous or arterial thrombus formation comprising administering a pharmaceutically effective amount of an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2 to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及包含C型凝集素样受体2（CLEC-2）抑制剂或CLEC-2活化剂抑制剂和任选的药学上可接受的载体，赋形剂和/或稀释剂的药物组合物。此外，本发明涉及C型凝集素样受体2（CLEC-2）的抑制剂或CLEC-2的活化剂的抑制剂，其用于治疗或预防与静脉或动脉血栓形成相关的病症或用于开发用于治疗或预防与静脉或动脉血栓形成相关的病症的药物的铅化合物。本发明还涉及治疗和/或预防与静脉或动脉血栓形成相关的病症的方法，包括给予药学有效量的C型凝集素样受体2（CLEC-2）抑制剂或对有需要的受试者的CLEC-2的激活剂。本发明还涉及鉴定适合作为铅化合物的化合物和/或用作治疗和/或预防与静脉或动脉血栓形成相关的病症的药物的方法。

5. 发明公开

EP2272874A1 Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation 审中-公开
标题翻译： Rolle von PLD1 bei der Thrombusbildung und Integrin-alpha-IIb-Beta-3-Aktivierung
公开(公告)号：EP2272874A1
公开(公告)日：2011-01-12
申请号：EP09009063.0
申请日：2009-07-10
申请人： CSL Behring GmbH , Julius-Maximilians-Universität Würzburg
发明人： Nieswandt, Bernhard , Stoll, Guido
IPC分类号： C07K16/40 , C12N9/20 , A61K39/395 , G01N33/50
CPC分类号： C07K16/40 , A01K2217/075 , A61K2039/505 , C12N9/20
摘要： The present invention relates to an inhibitor of phospholipase D1 (PLD1) or an inhibitor of an activator of PLD1 for use in treating or preventing a disorder related to venous or arterial thrombus formation or as a lead compound for developing a drug for treating or preventing a disorder related to venous or arterial thrombus formation. The present invention also relates to a method of treating and/or preventing a disorder related to venous or arterial thrombus formation comprising administering a pharmaceutically effective amount of an inhibitor of phospholipase D1 (PLD1) or an inhibitor of an activator of PLD1 to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及磷脂酶D1（PLD1）抑制剂或PLD1活化剂抑制剂，其用于治疗或预防与静脉或动脉血栓形成有关的障碍，或作为用于开发用于治疗或预防与静脉或动脉血栓形成相关的紊乱。本发明还涉及治疗和/或预防与静脉或动脉血栓形成有关的病症的方法，其包括向受试者施用药学有效量的磷脂酶D1（PLD1）抑制剂或PLD1激活剂抑制剂需要。本发明还涉及鉴定适合作为铅化合物的化合物和/或用作治疗和/或预防与静脉或动脉血栓形成相关的病症的药物的方法。

6. 发明公开

EP2145900A1 Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation 审中-公开
标题翻译： Orai1（CRACM1）ist derBlutplättchen-SOC-Kanal und wesentlichfürdie pathologischen Thrombusbildung
公开(公告)号：EP2145900A1
公开(公告)日：2010-01-20
申请号：EP08012731.9
申请日：2008-07-15
申请人： CSL Behring GmbH , Julius-Maximilians-Universität Würzburg
发明人： Braun, Attila , Nieswandt, Bernhard , Varga-Szabó, Dávid
IPC分类号： C07K16/28 , A61P7/02
CPC分类号： C07K16/28
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of Orai1 or an inhibitor of an activator of Orai1 and optionally a pharmaceutically active carrier, excipient or diluent, for use in treating or preventing a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及一种药物组合物，其包含Orai1抑制剂或Orai1活化剂抑制剂和任选的药物活性载体，赋形剂或稀释剂，用于治疗或预防与静脉或动脉血栓形成相关的病症。

7. 发明申请

WO2009129980A1 METHOD FOR THE PREVENTION AND TREATMENT OF CANCER BY INHIBITION OF GPVI 审中-公开
标题翻译：通过抑制GPVI预防和治疗癌症的方法
公开(公告)号：WO2009129980A1
公开(公告)日：2009-10-29
申请号：PCT/EP2009/002864
申请日：2009-04-20
申请人： CSL BEHRING GMBH , KRONTHALER, Ulrich , Nieswandt, Bernhard
发明人： KRONTHALER, Ulrich , Nieswandt, Bernhard
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/3053
摘要： The invention provides an inhibitor of GPVI for the prevention and or therapy of cancer and also the use of such an inhibitor of GPVI in the manufacture of a medicament for the prevention and/or therapy of cancer. A further aspect of the invention are pharmaceutical formulations comprising a GPVI inhibitor, which are suitable for the treatment of cancer, preferably for skin cancer, more preferably for melanoma, and most preferably for malignant cutaneous melanoma.
摘要翻译：本发明提供了用于预防和/或治疗癌症的GPVI抑制剂，以及GPVI抑制剂在制备用于预防和/或治疗癌症的药物中的用途。本发明的另一方面是包含GPVI抑制剂的药物制剂，其适用于治疗癌症，优选用于皮肤癌，更优选用于黑素瘤，最优选用于恶性皮肤黑素瘤。

8. 发明公开

EP2279000A1 METHOD FOR THE PREVENTION AND TREATMENT OF CANCER BY INHIBITION OF GPVI 审中-公开
标题翻译：预防和治疗癌症的方法抑制BY GPVI
公开(公告)号：EP2279000A1
公开(公告)日：2011-02-02
申请号：EP09735503.6
申请日：2009-04-20
申请人： CSL Behring GmbH
发明人： KRONTHALER, Ulrich , Nieswandt, Bernhard
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/3053
摘要： The invention provides an inhibitor of GPVI for the prevention and or therapy of cancer and also the use of such an inhibitor of GPVI in the manufacture of a medicament for the prevention and/or therapy of cancer. A further aspect of the invention are pharmaceutical formulations comprising a GPVI inhibitor, which are suitable for the treatment of cancer, preferably for skin cancer, more preferably for melanoma, and most preferably for malignant cutaneous melanoma.

9. 发明公开

EP2272565A3 Prevention of thrombus formation and/or stabilization 审中-公开
标题翻译： Verhinderung der Bildung und / oder Stabilisierung von Thrombi
公开(公告)号：EP2272565A3
公开(公告)日：2012-03-28
申请号：EP10183075.0
申请日：2005-12-20
申请人： CSL Behring GmbH
发明人： Nieswandt, Bernhard , Renné, Thomas
IPC分类号： A61P7/02 , A61K39/395 , A61K38/56 , C07K16/36 , C07K16/40
CPC分类号： C07K16/36 , A61K38/55 , A61K38/556 , A61K38/56 , A61K38/57 , A61K39/3955 , A61K2039/505 , C07K16/40 , C07K2317/76 , Y02A50/414
摘要： The present disclosure relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and/or factor XIIa to prevent the formation and/or the stabilization of threedimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
摘要翻译：本公开涉及至少一种抗体和/或一种抑制因子用于抑制因子XII和/或因子XIIa以防止三维血栓的形成和/或稳定化的用途。它还涉及药物制剂和使用因子XII作为抗血栓形成靶标。

10. 发明公开

EP2272565A2 Prevention of thrombus formation and/or stabilization 审中-公开
标题翻译：防止血栓的形成和/或稳定
公开(公告)号：EP2272565A2
公开(公告)日：2011-01-12
申请号：EP10183075.0
申请日：2005-12-20
申请人： CSL Behring GmbH
发明人： Nieswandt, Bernhard , Renné, Thomas
IPC分类号： A61P7/02 , A61K39/395
CPC分类号： C07K16/36 , A61K38/55 , A61K38/556 , A61K38/56 , A61K38/57 , A61K39/3955 , A61K2039/505 , C07K16/40 , C07K2317/76 , Y02A50/414
摘要： The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and/or factor XIIa to prevent the formation and/or the stabilization of threedimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式